Axogen Q4: EPS Miss Amid Biologics Transition
Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Gross margin compression is driven by one-time regulatory costs and biologics conversion, expected to normalize as biologics pricing and payer coverage expand.
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
AxoGen (AXGN) Q4 Earnings Miss Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago.
Wasatch Micro Cap Fund Q4 2025 Performance Review
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and paninis, Mama's targets the deli area of grocery stores and warehouse clubs. On the downside, software distribution company Climb Global Solutions, Inc. was the Fund's leading laggard in the quarter.
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on Avance Nerve Graft, a pivotal regulatory inflection point. The BLA submission features over a decade of real-world outcomes, robust manufacturing validation, and clinical recovery rates in the low-80% range.
AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined
Axogen is compounding business capital at increasing returns which was reflected in Q2 earnings. The stock remains in a down-trend with investors compressing multiples paid on capital invested into the business. The range of potential outcomes remains broad which coincides with historical trends seen in market for this name.
Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript
Axogen, Inc. (NASDAQ:AXGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Jens Schroeder Kemp - Chief Marketing Officer Lindsey Hartley - Chief Financial Officer Michael D. Dale - President, CEO & Director Rick Ditto - Corporate Participant Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Christopher Thomas Pasquale - Nephron Research LLC David Louis Turkaly - Citizens JMP Securities, LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Michael Anthony Sarcone - Jefferies LLC, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Operator [Audio Gap] Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer.
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.05 per share a year ago.
AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
